ストックスクリーナーアプリを入手
6.96
2.50%
0.17
アフターアワーズ：
6.89
-0.07
-1.01%
前日終値:
$6.79
開ける：
$6.94
24時間の取引高:
28,388
Relative Volume:
0.53
時価総額：
$43.07M
収益：
$2.19M
当期純損益:
$-24.19M
株価収益率:
-0.8091
EPS:
-8.6017
ネットキャッシュフロー:
$-82.94M
1週間 パフォーマンス:
+0.14%
1か月 パフォーマンス:
+0.29%
6か月 パフォーマンス:
-25.64%
1年 パフォーマンス:
-35.26%
1日の値動き範囲:
$6.765
$7.3775
1週間の範囲:
$6.6113
$7.55
52週間の値動き範囲:
$3.76
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
名前
Aligos Therapeutics Inc
セクター
電話
(800) 466-6059
住所
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.96 | 42.02M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 再開されました | Jefferies | Buy |
| 2025-08-18 | 再開されました | H.C. Wainwright | Buy |
| 2024-08-19 | 開始されました | H.C. Wainwright | Buy |
| 2023-01-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-01-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-09 | 開始されました | SVB Leerink | Outperform |
| 2021-05-17 | 再開されました | Piper Sandler | Overweight |
| 2020-11-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 開始されました | JP Morgan | Overweight |
| 2020-11-10 | 開始されました | Jefferies | Buy |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Aligos Therapeutics Inc (ALGS) 最新ニュース
Insider Sell: Will Aligos Therapeutics Inc outperform its industry peers2026 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Bull Run: What analysts say about Aligos Therapeutics Inc stockWeekly Profit Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
The Technical Signals Behind (ALGS) That Institutions Follow - Stock Traders Daily
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peers2026 News Drivers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aligos Therapeutics (ALGS) 8th Annual MASH Investor Conference Summary - Quartr
If You Invested $1,000 in Aligos Therapeutics, Inc. (ALGS) - Stock Titan
ALGS Technical Analysis & Stock Price Forecast - Intellectia AI
Activity Recap: Can Aligos Therapeutics Inc weather a recessionTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
Quarterly Recap: Can Aligos Therapeutics Inc continue delivering strong returnsCEO Change & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Jefferies Lowers Price Target for Aligos Therapeutics (ALGS) to $48 | ALGS Stock News - GuruFocus
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential - Investing.com India
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential By Investing.com - Investing.com South Africa
Nikhil Aneja Net Worth (2026) - GuruFocus
What is HC Wainwright’s Estimate for ALGS Q1 Earnings? - Defense World
Precision Trading with Aligos Therapeutics Inc. (ALGS) Risk Zones - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
Aligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike - Stock Titan
Aligos Therapeutics (ALGS) accounting officer granted 9,450 stock options at $7.03 - Stock Titan
Aligos Therapeutics (ALGS) awards 37,485 stock options to officer Calhoun - Stock Titan
Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating on ALGS with $50 Price Target | ALGS Stock News - GuruFocus
Dip Buying: Can Aligos Therapeutics Inc weather a recessionWeekly Earnings Recap & Risk Managed Trade Strategies - baoquankhu1.vn
Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen - Defense World
Aug Highlights: Can Aligos Therapeutics Inc weather a recessionMarket Rally & Daily Entry Point Alerts - baoquankhu1.vn
Aligos Therapeutics Earnings Report: Q4 Overview - Sahm
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Bitget
Aligos Therapeutics (ALGS) Reports Lower Q4 Revenue and Advances Key Studies - GuruFocus
ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing - TradingView
Aligos Therapeutics Q4 net loss narrows - TradingView
Growth Report: Will Aligos Therapeutics Inc benefit from current market trendsM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan
ALGS SEC FilingsAligos Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
A Peek at Aligos Therapeutics's Future Earnings - Benzinga
Aligos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ALGS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Monday - Defense World
9 Pharma Trends To Watch In 2026 - Pharmaceutical Online
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play - TipRanks
Aligos Therapeutics Forms Death Cross, Signaling Potential Bearish Trend Ahead - Markets Mojo
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - The Manila Times
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - The Manila Times
Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Risk On: What is ILMNs P E ratio telling usJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Moving Averages: What analysts say about Aligos Therapeutics Inc stockMarket Growth Review & Fast Momentum Entry Tips - baoquankhu1.vn
Can Aligos Therapeutics Inc. continue delivering strong returnsRecession Risk & Trade Opportunity Analysis Reports - mfd.ru
Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily
Officer stock option holdings disclosed at Aligos Therapeutics (ALGS) - Stock Titan
Aligos Therapeutics Inc (ALGS) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):